TITAN PHARMACEUTICALS INC
DelistedCIK 910267fmd_0DEZRY0W77BGJK5ZQ94WKQMGS4Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Jun 30, 2025, 62 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 15 | 0 | 7 | 3 | 5 | 2 | 1 | 0 | – |
| Cost of revenue | – | 0 | 0 | 1 | 0 | 0 | 0 | – | – | – |
| Gross profit | – | 15 | 0 | 6 | 3 | 4 | 1 | – | – | – |
| Research and development | 5 | 6 | 10 | 7 | 5 | 6 | 6 | 5 | 2 | – |
| Selling, general and administrative | – | 5 | 5 | 7 | 12 | – | – | – | – | – |
| Total operating expenses | 8 | 11 | 15 | 15 | – | – | 11 | 11 | 7 | 5 |
| Operating income | (7) | 4 | (15) | (8) | (8) | (7) | (9) | (10) | (7) | (5) |
| Other non-operating income (expense) | (5) | 1 | 0 | (1) | 0 | (0) | 1 | 0 | 2 | (0) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0) | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (7) | (7) | (9) | – | – | – |
| Net income | (11) | 5 | (14) | (9) | (16) | (18) | (9) | (10) | (6) | (5) |
| Net income to common shareholders | (11) | 5 | (14) | (9) | (16) | – | (9) | (10) | – | – |